Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: PNRC1

Summary for PNRC1

Gene information	Gene symbol	PNRC1
	Ensembl ID	ENSG00000146278
	Entrez ID	10957
	Gene name	proline rich nuclear receptor coactivator 1
	Synonyms	B4-2\|PROL2\|PRR2
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: PNRC1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	1.28185	1.58e-15
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.751965	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.307787	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.997451	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.287244	2.23e-42
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.256156	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	0.578414	1.22e-05
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.293257	1.08e-09
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.49909	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.618391	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.554665	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.412708	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.411811	7.83e-04
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.436008	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	1.05859	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.474939	2.12e-24
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.300873	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.467105	2.06e-28
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.291292	1.98e-18
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.264757	1.84e-39
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.31734	2.21e-02
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.451863	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	-0.286898	3.82e-03
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.605475	8.70e-35
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.556865	9.44e-15
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.540188	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.505874	7.84e-25
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.297533	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.334851	3.31e-14
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.292278	5.60e-08
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	-0.295799	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	0.565552	1.02e-02
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.722902	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.629787	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.479645	2.63e-02
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-0.340435	3.84e-22
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.444551	4.63e-14
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.923314	5.75e-27
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.33307	6.56e-06
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.605823	2.27e-10
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.57874	1.57e-02
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	-0.333906	2.49e-31
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.324046	8.88e-14
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.412522	3.80e-33
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.444269	9.35e-12
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.502018	6.17e-08
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.853941	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	-0.25795	5.14e-42
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.253971	6.27e-34
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.413966	3.84e-15
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.444302	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.860639	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.646655	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.595893	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.731574	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.466443	2.26e-12
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-0.380507	1.11e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-0.922553	2.63e-04
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	-0.289053	1.80e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.404854	9.00e-22
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-0.298528	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	1.03949	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.348959	3.01e-41
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.402695	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.357684	1.03e-08
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.339904	3.46e-40
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.73992	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.407086	0.00e+00

Top

Expression of PNRC1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to PNRC1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating PNRC1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
PNRC1	hsa-miR-4795-3p	99.5287	NM_006813
PNRC1	hsa-miR-126-5p	99.1566	NM_006813
PNRC1	hsa-miR-4789-5p	97.7841	NM_006813
PNRC1	hsa-miR-4789-3p	96.9394	NM_006813
PNRC1	hsa-miR-1323	96.5444	NM_006813
PNRC1	hsa-miR-548o-3p	96.5444	NM_006813
PNRC1	hsa-miR-381-3p	95.2529	NM_006813
PNRC1	hsa-miR-300	95.2529	NM_006813
PNRC1	hsa-miR-369-3p	95.0344	NM_006813
PNRC1	hsa-miR-144-3p	94.9771	NM_006813
PNRC1	hsa-miR-3163	94.8514	NM_006813
PNRC1	hsa-miR-466	94.6251	NM_006813
PNRC1	hsa-miR-19b-3p	93.9089	NM_006813
PNRC1	hsa-miR-19a-3p	93.9089	NM_006813
PNRC1	hsa-miR-1227-3p	93.3972	NM_006813
PNRC1	hsa-miR-655-3p	93.2604	NM_006813
PNRC1	hsa-miR-374c-5p	93.2604	NM_006813
PNRC1	hsa-miR-320e	92.4279	NM_006813
PNRC1	hsa-miR-4699-3p	92.3731	NM_006813
PNRC1	hsa-miR-4643	91.7947	NM_006813
PNRC1	hsa-miR-4671-3p	91.7794	NM_006813
PNRC1	hsa-miR-4668-5p	91.5128	NM_006813
PNRC1	hsa-miR-4282	91.3459	NM_006813
PNRC1	hsa-miR-23a-3p	90.7875	NM_006813
PNRC1	hsa-miR-23c	90.7875	NM_006813
PNRC1	hsa-miR-23b-3p	90.7875	NM_006813
PNRC1	hsa-miR-101-3p	90.3894	NM_006813
PNRC1	hsa-miR-6800-3p	90.1857	NM_006813
PNRC1	hsa-miR-524-5p	89.9972	NM_006813
PNRC1	hsa-miR-520d-5p	89.9972	NM_006813
PNRC1	hsa-miR-3941	89.8603	NM_006813
PNRC1	hsa-miR-222-5p	88.9652	NM_006813
PNRC1	hsa-miR-199a-3p	88.1732	NM_006813
PNRC1	hsa-miR-199b-3p	88.1732	NM_006813
PNRC1	hsa-miR-3129-5p	88.1732	NM_006813
PNRC1	hsa-miR-6866-5p	87.8228	NM_006813
PNRC1	hsa-miR-16-1-3p	87.7124	NM_006813
PNRC1	hsa-miR-216b-3p	87.1279	NM_006813
PNRC1	hsa-miR-297	86.8045	NM_006813
PNRC1	hsa-miR-7113-5p	86.7534	NM_006813
PNRC1	hsa-miR-495-3p	84.7477	NM_006813
PNRC1	hsa-miR-5688	84.6713	NM_006813
PNRC1	hsa-miR-450b-5p	84.0305	NM_006813
PNRC1	hsa-miR-484	82.6025	NM_006813
PNRC1	hsa-miR-3149	82.408	NM_006813
PNRC1	hsa-miR-7-2-3p	81.9191	NM_006813
PNRC1	hsa-miR-7-1-3p	81.9191	NM_006813
PNRC1	hsa-miR-944	81.6339	NM_006813
PNRC1	hsa-miR-4802-3p	80.8507	NM_006813
PNRC1	hsa-miR-548p	80.2806	NM_006813

Page: 1

Top

Motifs and transcription factors (TFs) regulating PNRC1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
PNRC1	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
PNRC1	metacluster_198.7	AHR; ZBTB14; ZBTB14; ZBTB14 (directAnnotation).
PNRC1	hdpi__TP73	TP73 (directAnnotation).
PNRC1	taipale_tf_pairs__ERF_HES7_NCCGGAANNNNNNCACGYGNN_CAP_repr	ERF; HES7 (directAnnotation).
PNRC1	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNNCACGTGNN_CAP_repr	ETV2; HES7 (directAnnotation).
PNRC1	kznf__ZNF25_Imbeault2017_OM_MEME	ZNF25 (directAnnotation).
PNRC1	metacluster_195.2	EGR2; KLF10; KLF10; KLF11; KLF11; KLF11; KLF13; KLF13; KLF13; KLF13; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF15; KLF15; KLF16; KLF3; KLF8; KLF9; KLF9; KLF9; SP1; SP1; SP1; SP3; SP3; SP4; SP8; SP8; SP8; SP9; SP9 (directAnnotation). EGR1; KLF1; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF2; KLF3; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF9; SP1; SP3; SP4; SP4; SP5; SP5; SP5; SP6; SP7; SP8; SP9 (inferredBy_Orthology).
PNRC1	metacluster_3.14	WT1; WT1 (directAnnotation).
PNRC1	swissregulon__hs__ZBTB14	ZBTB14 (directAnnotation).
PNRC1	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
PNRC1	metacluster_131.7	EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; EGR3; EGR3; EGR3; EGR3; EGR4; EGR4; WT1 (directAnnotation). EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; WT1; ZBTB43; ZBTB43; ZBTB43; ZBTB43; ZBTB5; ZBTB5; ZBTB5; ZBTB5; ZBTB7A; ZBTB7A; ZBTB7A; ZBTB7A; ZNF367; ZNF367; ZNF367; ZNF367; ZNF740; ZNF740; ZNF740; ZNF740 (inferredBy_Orthology).
PNRC1	taipale_cyt_meth__ZNF281_NCCCCTCCCCCN_eDBD_meth	ZNF281 (directAnnotation).
PNRC1	metacluster_3.11	SP1; SP1; SP2; SP3; SP3; SP4 (directAnnotation).
PNRC1	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
PNRC1	metacluster_3.7	SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation).
PNRC1	transfac_pro__M01714	KLF15 (directAnnotation).
PNRC1	hocomoco__PROX1_HUMAN.H11MO.0.D	PROX1 (directAnnotation).
PNRC1	metacluster_126.3	LIN28B; LIN28B (directAnnotation).
PNRC1	metacluster_3.5	KLF14; KLF15; KLF15; KLF16 (directAnnotation).
PNRC1	taipale_tf_pairs__GCM1_ELF1_GTGCGGGCGGAAGTN_CAP_repr	ELF1; GCM1 (directAnnotation).
PNRC1	transfac_pro__M02898	SMAD3 (directAnnotation).
PNRC1	metacluster_174.3	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).
PNRC1	transfac_pro__M06035	ZNF749 (directAnnotation).
PNRC1	metacluster_174.2	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).
PNRC1	hocomoco__KLF13_HUMAN.H11MO.0.D	KLF13 (directAnnotation).
PNRC1	kznf__ZBTB14_Schmitges2016_RCADE	ZBTB14 (directAnnotation).
PNRC1	transfac_pro__M07436	WT1 (directAnnotation).
PNRC1	swissregulon__hs__CHD1	CHD1 (directAnnotation).
PNRC1	hdpi__HIP2	UBE2K (directAnnotation).
PNRC1	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
PNRC1	metacluster_133.1	ZNF304; ZNF304; ZSCAN22 (directAnnotation).
PNRC1	kznf__ZNF441_Imbeault2017_RP_RCADE	ZNF441 (directAnnotation).
PNRC1	metacluster_163.1	KLF1; KLF1; KLF1; KLF1; KLF1; KLF1; KLF1; KLF10; KLF10; KLF12; KLF12; KLF12; KLF13; KLF16; KLF17; KLF2; KLF3; KLF3; KLF3; KLF3; KLF4; KLF4; KLF4; KLF4; KLF4; KLF5; KLF5; KLF5; KLF5; KLF6; KLF6; KLF6; KLF7; KLF9; KLF9; SALL4; SP1; ZNF148; ZNF148; ZNF526 (directAnnotation). EGR4; KLF1; KLF1; KLF12; KLF12; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF3; KLF4; KLF4; KLF4; KLF4; KLF4; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF8; KLF9; SP4; SP5; SP5; SP6; SP7; SP8; SP9; ZNF526 (inferredBy_Orthology).
PNRC1	transfac_pro__M01783	SP2 (directAnnotation).
PNRC1	metacluster_111.3	ATF1; ATF3; CREB1; CREB1; CREB1; CREB1; CREB1; CREM; CREM; CREM; CREM; E4F1; E4F1 (directAnnotation). CREB1; CREB1; CREM; JDP2 (inferredBy_Orthology).
PNRC1	jaspar__MA0748.2	YY2 (directAnnotation).
PNRC1	tfdimers__MD00432	DBP; STAT1 (directAnnotation).
PNRC1	tfdimers__MD00084	ARID3A; NKX2-4 (directAnnotation).
PNRC1	metacluster_111.4	ATF1; ATF1; ATF1; ATF1; ATF1; ATF1; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF3; ATF3; ATF3; ATF3; ATF3; ATF4; ATF4; ATF5; ATF6; ATF6B; ATF7; ATF7; ATF7; BATF3; BATF3; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB3; CREB3L4; CREB3L4; CREB5; CREB5; CREB5; CREM; CREM; CREM; CREM; CREM; FOSB; FOSL1; FOSL1; FOSL2; JDP2; JDP2; JDP2; JUN; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; XBP1; XBP1; XBP1; ZNF629 (directAnnotation). ATF1; ATF1; ATF1; ATF2; ATF2; ATF3; ATF6; ATF6B; ATF7; ATF7; ATF7; ATF7-NPFF; ATF7-NPFF; ATF7-NPFF; ATF7-NPFF; BATF; BATF2; BATF3; CREB1; CREB1; CREB3; CREB3L1; CREB3L2; CREB3L3; CREB3L4; CREM; FOS; FOSB; FOSL1; FOSL2; JDP2; JDP2 (inferredBy_Orthology).
PNRC1	transfac_public__M00280	RFX1 (directAnnotation).
PNRC1	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_repr	ZNF385D (directAnnotation).
PNRC1	metacluster_141.4	GLIS2 (directAnnotation).
PNRC1	transfac_pro__M02279	CREB1 (directAnnotation).
PNRC1	metacluster_180.3	ATF2; ATF2; ATF2; ATF2; ATF3; ATF3; ATF4; ATF4; ATF6; ATF6B; ATF7; ATF7; BACH2; BATF3; BATF3; CREB1; CREB1; CREB3; FOSL1; FOSL2; JDP2; JUN; JUN; JUN; JUND; JUND; XBP1; ZBTB21 (directAnnotation). JDP2; JDP2; JUND (inferredBy_Orthology).
PNRC1	transfac_public__M00039	CREB1 (directAnnotation).
PNRC1	transfac_pro__M05667	ZNF35 (directAnnotation).
PNRC1	taipale_tf_pairs__MYBL1_TBX21_AGGTGTGNCSGTTR_CAP_repr	MYBL1; TBX21 (directAnnotation).
PNRC1	transfac_pro__M00687	NFYC (directAnnotation). NFYA (inferredBy_Orthology).
PNRC1	transfac_pro__M04746	E2F1 (directAnnotation).
PNRC1	metacluster_65.8	ZNF343 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."